SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-19-000987
Filing Date
2019-12-26
Accepted
2019-12-26 16:01:31
Documents
2
Group Members
ORBIMED CAPITAL GP V LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 ss161324_sc13da.htm SC 13D/A 78707
2 JOINT FILING AGREEMENT ss161324_ex9901.htm EX-99.1 6302
  Complete submission text file 0000947871-19-000987.txt   86632
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Subject) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89113 | Film No.: 191310590
SIC: 2834 Pharmaceutical Preparations